China Sets New Rule For Drug Price Differentiation
This article was originally published in PharmAsia News
China’s National Development and Reform Commission Dec. 2 releases new regulation on drug price differentiation intended to close loopholes.
You may also be interested in...
China's Next Round Of Drug Price Cuts? NDRC To Slash Prices On More Products On National Drug Reimbursement List
SHANGHAI - China's New Drug Price Guidelines are expected to be released by the end of this year, which are likely to lead to another round of price cuts on drugs included on the National Drug Reimbursement List, according to analysts
BEIJING - In the government's latest move to expand coverage under sweeping health system reforms that are in the works China-wide, the Ministry of Human Resources and Social Security has added hundreds of new medicines to the latest edition of the national drug reimbursement catalog
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.